Article Sidebar
Published:
Apr 28, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of combined treatment with benazepril and spironolactone on diabetic nephropathy and serum levels of IL-6, CRP and TNF-α
Abstract
Purpose: To study the therapeutic effect of a combination of benazepril and spironolactone on diabetic nephropathy patients, and also to determine the influence of the combined treatment on serum IL-6, CRP and TNF-α.
Methods: 100 diabetic nephropathy patients admitted to The Affiliated Hospital of Inner Mongolia Medical University from April 2019 to October 2020 were randomly chosen and divided into groups E and F by drawing lots (n = 50 each). Group E received benazepril, while group F received a combined treatment of benazepril and spironolactone. Therapeutic efficacy, incidence of adverse drug reactions, and renal function after treatment, as well as IL-6, CRP and TNF-α levels in serum pre- and posttreatment, were determined. Fasting blood glucose (FBG) levels were also measured pre-treatment, and at 7 days and 14 days post-exposure to drugs.
Results: Therapeutic efficacy and renal functions were significantly better in group F than in group E, while post-treatment incidence of adverse drug reactions, and expression levels of CRP, IL-6, and TNF-α levels were significantly reduced in group F, relative to group E (p < 0.05). Following treatment, the inflammatory factor levels were decreased in both groups.
Conclusion: The combination of benazepril and spironolactone produces higher treatment effect in diabetic nephropathy patients than those that received benazepril only. The combined treatment is recommended in the management of diabetic nephropathy patients.
